How a microbial‑first CDMO turns complex nanoparticle concepts into clinical‑grade candidates TL;DRBiologic nanoparticles (including VLPs and engineered protein assemblies) offer precise antigen display, tunable valency, and new immune‑engagement mechanisms. A microbial‑first approach reduces cost and time while improving manufacturability. Below is a six‑stage playbook—from scoping to scale‑up—plus pitfalls to avoid, where VLPs fit now, and […]
Tag: Bacteria CDMO
Plasmid DNA & mRNA Manufacturing: How a Microbial-First CDMO Unlocks the Next Wave of Biologics
At Mika Biologics, we build manufacturability by default. Microbes are our engine. Speed, quality, and scale are the outputs. Executive take Plasmid DNA & mRNA manufacturing now sits at the backbone of modern biologics—from genetic vaccines and in vivo gene editing to engineered cell therapies and next-generation immuno-oncology. Demand for fast, GMP-grade supply chains is […]
Endotoxin-Free Biologics: Preventing LPS at the Source
Biologics have transformed medicine. Monoclonal antibodies, cytokines, vaccines, enzymes, and nanoparticles are no longer niche—they dominate the global pharmaceutical pipeline and generate revenues in the hundreds of billions. Yet one microscopic adversary continues to sabotage this progress: endotoxins. Lipopolysaccharide (LPS), shed from Gram-negative bacteria, is the hidden saboteur of biologics manufacturing. At picogram levels, it […]
What You Should Look for in a Bacterial CDMO (And Why It Matters)
Introduction: Why Bacteria Are Back in the Spotlight For decades, mammalian cell systems have hogged the limelight in biologics manufacturing. Think monoclonal antibodies, blockbuster immunotherapies, and all the glamorous biotech headlines. But here’s the plot twist: bacteria never left the stage. In fact, they’re stepping back into the spotlight, and this time they’re dressed for […]